From the Research Institute for Fragrance Materials, Inc, Woodcliff Lake, NJ.
DABMEB Consultancy, Ltd, Gloucestershire, United Kingdom.
Dermatitis. 2021;32(5):339-352. doi: 10.1097/DER.0000000000000684.
The human repeated insult patch test (HRIPT) has a history of use in the fragrance industry as a component of safety evaluation, exclusively to confirm the absence of skin sensitization at a defined dose.
The aim of the study was to document the accumulated experience from more than 30 years of conducting HRIPTs.
A retrospective collation of HRIPT studies carried out to a consistent protocol was undertaken, with each study comprising a minimum of 100 volunteers.
The HRIPT outcomes from 154 studies on 134 substances using 16,512 volunteers were obtained. Most studies confirmed that at the selected induction/challenge dose, sensitization was not induced. In 0.12% of subjects (n = 20), there was induction of allergy. However, in the last 11 years, only 3 (0.03%) of 9854 subjects became sensitized, perhaps because of improved definition of a safe HRIPT dose from the local lymph node assay and other skin sensitization methodologies, as well as more rigorous application of the standard protocol after publication in 2008. This experience with HRIPTs demonstrates that de novo sensitization induction is rare and becoming rarer, but it plays an important role as an indicator that toxicological predictions from nonhuman test methods (in vivo and in vitro methods) can be imperfect.
人体重复激惹斑贴试验(HRIPT)在香料行业中被广泛用于安全性评估,专门用于确认在规定剂量下是否不存在皮肤致敏性。
本研究旨在记录 30 多年来进行 HRIPT 的积累经验。
对按照一致方案进行的 HRIPT 研究进行回顾性整理,每个研究至少包含 100 名志愿者。
共获得了 134 种物质 154 项研究、涉及 16512 名志愿者的 HRIPT 结果。大多数研究证实,在选定的诱导/挑战剂量下,未诱导出致敏性。在 0.12%的受试者(n=20)中,出现了过敏反应。然而,在过去的 11 年中,仅在 9854 名受试者中的 3 名(0.03%)发生了致敏,这可能是由于局部淋巴结试验和其他皮肤致敏性方法对安全 HRIPT 剂量的定义更加明确,以及在 2008 年发表后对标准方案的更严格应用。HRIPT 的经验表明,新的致敏诱导很少见,且越来越罕见,但它作为一种指标,表明非人类测试方法(体内和体外方法)的毒理学预测可能并不完美。